|Grant Affiliation:||Shattock: Novel Antigens for Mucosal Protection|
|Strategy:||Protein & peptide vaccines|
|Study Type:||Pre-Clinical Non-NHP|
|Study Start Date:||2008-12-16|
|Study Made Public:||2011-02-25|
Neutralization activity of sera collected from rabbits immunized with a recombinant clade C HIV gp140, formulated with various adjuvants, by the subcutaneous and intravaginal routes.
CAVD 298 is a preclinical rabbit study comparing protein and adjuvant regimens administered by subcutaneous and intravaginal routes.
Sign in to see full information about this study and to download study data.
No integrated data is available for this study.
No non-integrated data is available for this study.